Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas; and finished dosage form anti-infective. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The company's Alcon segment offers intraocular lenses and equipment for cataract procedures; equipment, instruments, and devices for vitreoretinal surgeries; surgical equipment and diagnostic devices for refractive surgical procedures; and devices to treat glaucoma. It also provides viscoelastics, surgical solutions, diagnostic ophthalmic products, surgical packs, and other disposable products for cataract and vitreoretinal surgery. In addition, this segment offers contact lenses and ocular health products; over-the-counter ophthalmic products; eye drops for the temporary relief of ocular itching due to allergies; vitamins for ocular health; and iLux Device, a therapeutic device used to treat meibomian gland dysfunction. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Ligand Pharmaceuticals, Inc.; Amgen; University of California, Berkeley; Bristol-Myers Squibb; IBM Watson Health; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; Conatus Pharmaceuticals Inc.; and TRIO. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone011-41-61-324-1111
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$51.90 billion
Profitability
Miscellaneous
Employees125,161
Next Earnings Date7/17/2019 (Estimated)
OptionableOptionable
Novartis (NYSE:NVS) Frequently Asked Questions
What is Novartis' stock symbol?
Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."
How often does Novartis pay dividends? What is the dividend yield for Novartis?
Novartis declared an annual dividend on Thursday, January 31st. Stockholders of record on Tuesday, March 5th will be paid a dividend of $2.8646 per share on Wednesday, March 13th. This represents a dividend yield of 3.27%. The ex-dividend date of this dividend is Monday, March 4th. This is a boost from Novartis's previous annual dividend of $2.33. View Novartis' Dividend History.
How were Novartis' earnings last quarter?
Novartis AG (NYSE:NVS) posted its earnings results on Wednesday, April, 24th. The company reported $1.21 EPS for the quarter, topping analysts' consensus estimates of $1.11 by $0.10. The firm had revenue of $11.11 billion for the quarter, compared to analyst estimates of $11.76 billion. Novartis had a net margin of 24.55% and a return on equity of 16.75%. Novartis's quarterly revenue was up 1.7% compared to the same quarter last year. During the same period last year, the firm posted $1.28 EPS. View Novartis' Earnings History.
When is Novartis' next earnings date?
What price target have analysts set for NVS?
16 Wall Street analysts have issued 1 year target prices for Novartis' stock. Their forecasts range from $74.71 to $105.00. On average, they anticipate Novartis' stock price to reach $85.8840 in the next twelve months. This suggests a possible upside of 2.4% from the stock's current price. View Analyst Price Targets for Novartis.
What is the consensus analysts' recommendation for Novartis?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 4 sell ratings, 3 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.
Has Novartis been receiving favorable news coverage?
Media coverage about NVS stock has trended positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Novartis earned a media sentiment score of 2.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the next several days.
Who are some of Novartis' key competitors?
Some companies that are related to Novartis include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Abbott Laboratories (ABT), AbbVie (ABBV), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Celgene (CELG), Bayer (BAYRY) and Shire (SHPG).
What other stocks do shareholders of Novartis own?
Who are Novartis' key executives?
Novartis' management team includes the folowing people:
- Dr. Vasant Narasimhan, Chief Exec. Officer (Age 43)
- Mr. Harry Kirsch, Chief Financial Officer (Age 54)
- Mr. Steffen Lang, Global Head of Technical Operations (Age 52)
- Ms. Shannon Thyme Klinger, Group Gen. Counsel (Age 48)
- Dr. Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer (Age 51)
Who are Novartis' major shareholders?
Novartis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (1.03%), BlackRock Inc. (0.44%), FMR LLC (0.38%), Loomis Sayles & Co. L P (0.30%), Boston Partners (0.28%) and Mawer Investment Management Ltd. (0.25%).
Which major investors are selling Novartis stock?
NVS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Boston Partners, Marshall Wace North America L.P., Fort Washington Investment Advisors Inc. OH, Connor Clark & Lunn Investment Management Ltd., Renaissance Technologies LLC, First Trust Advisors LP and Wellington Management Group LLP.
Which major investors are buying Novartis stock?
NVS stock was bought by a variety of institutional investors in the last quarter, including Lazard Asset Management LLC, FMR LLC, Primecap Management Co. CA, Mawer Investment Management Ltd., Voya Investment Management LLC, Charles Schwab Investment Management Inc., Aristotle Capital Management LLC and Janus Henderson Group PLC.
How do I buy shares of Novartis?
Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novartis' stock price today?
One share of NVS stock can currently be purchased for approximately $83.91.
How big of a company is Novartis?
Novartis has a market capitalization of $193.83 billion and generates $51.90 billion in revenue each year. The company earns $12.61 billion in net income (profit) each year or $5.09 on an earnings per share basis. Novartis employs 125,161 workers across the globe.
What is Novartis' official website?
How can I contact Novartis?
Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 011-41-61-324-1111 or via email at [email protected]
MarketBeat Community Rating for Novartis (NYSE NVS)
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
